コンテンツへスキップ
Merck

SML3228

Rimiducid

≥90% (HPLC), FKBP12 F36V mutant cross-linker, powder

別名:

(S,2S,2′S)-((1R,1′R)-1,1′-(3,3′-(2,2′-(Ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(oxy)bis(3,1-phenylene))bis(3-(3,4-dimethoxyphenyl)propane-1,1-diyl)) bis(1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate), 1,1′-{Ethylenebis[azanediyl(2-oxoethane-2,1-diyl)oxy-3,1-phenylene]}bis[(1R)-3(3,4-dimethoxyphenyl)propyl]bis{(2S)-1-[(2S)-2-(3,4,5trimethoxyphenyl)butanoyl]piperidine-2-carboxylate}, 2,2′-[1,2-Ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene[(1R)-3-(3,4-dimethoxyphenyl)propylidene]]] bis[(2S)-1-[(2S)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-2-piperidinecarboxylate], AP 1903, AP-1903, AP1903

ログインで組織・契約価格をご覧ください。

サイズを選択してください

この商品について

実験式（ヒル表記法）:
C78H98N4O20
CAS番号:
195514-63-7
分子量:
1411.63
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD25976784

主要文書

すべての文書を表示
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

Rimiducid, ≥90% (HPLC)

SMILES string

N2([C@@H](CCCC2)C(=O)O[C@H](CCc8cc(c(cc8)OC)OC)c3cc(ccc3)OCC(=O)NCCNC(=O)COc4cc(ccc4)[C@H](OC(=O)[C@H]6N(CCCC6)C(=O)[C@@H](CC)c7cc(c(c(c7)OC)OC)OC)CCc5cc(c(cc5)OC)OC)C(=O)[C@@H](CC)c1cc(c(c(c1)OC)OC)OC

InChI key

GQLCLPLEEOUJQC-ZTQDTCGGSA-N

assay

≥90% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

Quality Level

100

関連するカテゴリー

Biochem/physiol Actions

High-affinity FKBP12 F36V mutant cross-linker for Chemical Induction of Dimerization (CID) of Chimeric Antigen Receptor (CAR) in vitro and in vivo.
Rimiducid (AP1903) is a homodimeric FKBP12 Phe36Val (F36V-FKBP, FKBP-F36V) mutant-selective cross-linker composed of two high-affinity ligands, each with 713-fold selectivity over endogenous FKBP (Kd = 94 pM/F36V- vs 67 nM/Wt-FKBP using 4′-AF-labeled rimiducid). Rimiducid activates signaling events via Chemical Induction of Dimerization (CID) by cross-linking FKBP12-F36 fusions (Chimeric Antigen Receptor or CAR) expressed in cells in cultures (apoptosis induction EC50 = 0.1 nM; HT1080 expressing FKBP(F36V)-Fas intracellular domain) and in animals in vivo (EC50 = 0.4 mg/kg i.v. in a murine model of conditional cell ablation).

保管分類

11 - Combustible Solids

wgk

WGK 3

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number
0000470613
0000470613
0000389464
0000389465
0000389465

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

COAを検索

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Dongpeng Jiang et al.
Leukemia, 34(3), 821-830 (2019-10-19)
CD19-redirected CAR-T immunotherapy has emerged as a promising strategy for treatment of B cell lymphoma, however, many patients often relapsed due to antigen loss. Therefore, it is urgently needed to explore other suitable antigens targeted by CAR-T cells to cure
D C Thomis et al.
Blood, 97(5), 1249-1257 (2001-02-27)
Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation. One strategy to treat GVHD is to equip donor T cells with a conditional suicide mechanism that can be triggered when GVHD occurs. The herpes simplex virus thymidine
Xiaoou Zhou et al.
Blood, 125(26), 4103-4113 (2015-05-16)
To test the feasibility of a single T-cell manipulation to eliminate alloreactivity while sparing antiviral and antitumor T cells, we infused 12 haploidentical hematopoietic stem cell transplant patients with increasing numbers of alloreplete haploidentical T cells expressing the inducible caspase
Kenneth A Matreyek et al.
Nucleic acids research, 48(1), e1-e1 (2019-10-16)
Multiplex genetic assays can simultaneously test thousands of genetic variants for a property of interest. However, limitations of existing multiplex assay methods in cultured mammalian cells hinder the breadth, speed and scale of these experiments. Here, we describe a series
Carolina Berger et al.
Blood, 103(4), 1261-1269 (2003-10-18)
Conditional suicide genes derived from pathogens have been developed to confer drug sensitivity and enhance safety of cell therapy, but this approach is limited by immune responses to the transgene product. We examined a strategy to regulate survival of transferred
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）